Eidos' $106 million IPO comes on the heels of a $64 million series B and will support phase 2 and phase 3 trials of its TTR amyloidosis drug.

Anika's hopes of a mid-2019 U.S. approval for arthritis drug Cingal are dashed by a late-stage trial miss, but it's not giving up on the project.

The MPM Capital-led series B tees iTeos up to start dosing patients with an adenosine A2A antagonist later this year.

TG Therapeutics will fund and run early-phase clinical trials of the treatment for hematologic B-cell malignancies.

The data, taken from three patients, showed a 38% increase in a muscle protein that boys with DMD usually lack.

Vertex's newly expanded site covers 170,000 square feet, boosting Vertex’s ability to hunt for the next generation of blockbusters.

Can-Fite won’t get a readout from its midstage trial of liver cancer drug namodenoson as soon as hoped, but says the data so far are looking good.

Syncona committed £85 million to Freeline, maintaining a big stake in a biotech that aims to redefine treatment of hemophilia B and Fabry disease.

Longtime Cowen analyst Eric Schmidt is joining Arie Belldegrun's latest CAR-T startup, Allogene.

Medivir's hopes of starting a pivotal trial of its HDAC inhibitor in lymphoma this year have hit a snag as it can't agree on a design with the FDA.